- Hindi news
- Cataracts Will No Longer Require Operation; Will Be Extracted From Aspirin made IDrops, 20 Million Cases Come Every Year
new Delhi5 minutes ago
- Copy link
In the lab, model protein and model peptides that make up the eye lens were prepared, and the use of aspirin nanorods was found to prevent the formation of peptide-like tubular structures.
- Institute of Nanoscience and Technology developed nanorods from aspirin drug
- If all further tests are successful, the idrop will be in the market in 3 years
Anirudh Sharma. A team of scientists from the Indian government's Institute of Nano Science and Technology, Mohali, has developed nanorods (extremely fine particles) from aspirin, a drug used to reduce pain or fever, a lab test to prevent cataracts, the major cause of blindness. Have proved successful in
Presently, the treatment for cataract is surgery. This is the first case in the country to develop nanorods from aspirin. If all the tests are successful, then by 2023 its drug will come in the market in the form of Iderap. In cataracts the eye blur material is removed and the natural lens of the eye is replaced by new artificial lenses if needed.
12 million people in the country are blind
There are about 12 million blind people in the country. 66.2% of these blindness is due to cataract. Every year, 2 million new cases are reported in the country. The head of this research team, Dr. Jiban Jyoti Panda, said that due to aging, the formation of crystalline protein in the eye deteriorates due to mutations or due to the direct exposure of the ultraviolet raz to the eyes.
This causes disordered proteins to accumulate and form a blue or brown layer, thereby deleting the transparency of the lens. This is called cataract. Cataracts stop appearing. Aspirin nanorods prevent the crystalline protein of the eye and its fragmentation of peptides, which are important causes of cataract.
In the lab, model protein and model peptides that make up the eye lens were prepared, and the use of aspirin nanorods was found to prevent the formation of peptide-like tubular structures. The experiment yielded two types of results. First- it breaks down the assembled proteins. Second, it does not allow new proteins to be formed. In other words, if a cataract has been formed, it will dissolve and eliminate the possibility of getting a new cataract.
Aspirin's safety profile was known, clinical trials will also ease
Dr. Panda reported that lab testing was the use of aspirin repurposing, which has been successful. Choosing a new molecule would have to go through a very long process, but aspirin is already being used, so we know its safety profile. It will also be easier to allow clinical trials.